efpeglenatide

Efpeglenatide is a long-acting glucagon-like peptide 1 receptor agonist (GLP-1 RA) designed for the treatment of type 2 diabetes and obesity. It is a synthetically modified exendin analog (CA-exendin-4) conjugated to the fragment crystallizable (Fc) region of human immunoglobulin G4 via a mini-polyethylene glycol linker. This structure extends its half-life and allows for flexible dosing regimens, including once-weekly or potentially once-monthly subcutaneous administration. Efpeglenatide mimics endogenous GLP-1 by binding to the glucagon-like peptide 1 receptor, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and promoting weight loss. The molecule’s design reduces degradation by dipeptidyl peptidase 4 (DPP-IV), decreases renal clearance due to increased molecular size from Fc conjugation, and minimizes loss of activity from antidrug antibodies. Clinical trials have shown significant improvements in glycemic control and body weight reduction compared with placebo[3][5][6][7].

Brand names

Efpeglenatide

Other names

efpeglenatideLAPS-Exendin-4LAPS-Exendin4LAPS-Exendin 4